Figure 1. Drugs and targets for treatment of AML. A) Approved drugs and targets. B) Selected ongoing clinical trials. BCL2: B-cell lymphoma 2; CD33, CD47: cluster of differentiation 33 and 47; FLT3 mut: mutant fms-like tyrosine kinase; IDH1 mut: mutant isocitrate dehydrogenase 1; NPM mut: mutant nucleophosmin 1; KMT2A: lysine-specific methyltransferase 2A.